Capability for global drug development
  •  Researchers with global R & D capabilities as major shareholders.
  •  Possibility of complex interdisciplinary R&D for new drug development.
    (In vitro, in sillco, in vivo Screening, drug design, synthesis, genome-wide analysis, ADME_PK study, BBB penetration study, general toxicology etc.
Position / Area
Paul Youngho Kim
R&D head
NIH research fellow
Ph.D. Seoul National Univ.
Jeewoo Lee
Head Scientist Co-founder
Professor Seoul National Univ.
School of Pharmacy
NIH research fellow
Ph.D.SUNY Buffalo
Inhee MooK-Jung
Head Scientist Co-founder
Alzheimer's disease
Professor Seoul National Univ
School of Medicine
Ph.D. Univ. of Arizona
Min Jung
Adivisory board Co-founder
Animal Model
Professor of KAIST
Ph.D. UC Irvine
Sukjae Chung
Advisory board
Professor Seoul National Univ.
School of Pharmacy
Ph.D.SUNY Buffalo
  Capability of out-licensing business
  •  Management team with multinational company experience and business success experience
  •  Four overseas, two domestic licensing experience

    - Network for out-license with overseas pharmaceutical companies
    -  Negotiation skills and experience
    -  Signed contract for support of licensed international lawyer and consulting firm

  Securing R & D pipeline with global competitiveness
  •  Pipeline for new drug development: TRPV1 antagonist for neuropathic pain analgesics, TRPV1 agonist for topical pain treatment, Alzheimer's disease modifying drug, early diagnosis kit for Alzheimer's disease, etc.
  •  Several number of candidates for each pipeline
    -  Alzheimer's disease modifying drug: securing four candidate substances
    -  TRPV1 antagonist for neuropathic pain: securing various compound analogues, numerous patent applications
    -  TRPV1 agonist for topical pain treatment: securing various compound analogues, numerous patent applications

Non-narcotic strong analgesics out-licensed to Grünenthal
Acute & Chronic Severe Pain Reliever out-licensed to Grünenthal
Joint research and development with Daewoong Pharmaceutical for Alzheimer's disease drug
(Αβ oligomerization inhibitor)
Out-license and co-development deal with Roche for Alzheimer's disease treatment
(RAGE modulator)
Joint research with NIH for topical application of neuropathic pain treatment